Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Shoushtari
    Shoushtari
  8. Cheung
    Cheung
  9. Voss
    Voss
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)
  7. Epidemiology and Biostatistics (153)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Surgery (123)
  10. Survivorship Research (120)
Search Within
Formats
  1. Journal Article (751)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (11)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Sandra D'Angelo (26)

More People

Years
  1. 2025 (40)
  2. 2024 (60)
  3. 2023 (44)
  4. 2022 (122)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (412)
  2. Breast Cancer Research (67)
  3. BMC Cancer (65)
  4. Genome Biology (47)
  5. Journal of Hematology & Oncology (43)
  6. Journal of Translational Medicine (35)

More Publications

Results (1092)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
    Journal Article

    Manitz, J.; D'Angelo, S. P.; Apolo, A. B.; Eggleton, S. P.; Bajars, M.; Bohnsack, O.; Gulley, J. L.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
    Journal Article

    Schöffski, P.; Tan, D. S. W.; Martín, M.; Ochoa-de-Olza, M.; Sarantopoulos, J.; Carvajal, R. D.; Kyi, C.; Esaki, T.; Prawira, A.; Akerley, W.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer
    Journal Article

    Prasad, M.; Zorea, J.; Jagadeeshan, S.; Shnerb, A. B.; Mathukkada, S.; Bouaoud, J.; Michon, L.; Novoplansky, O.; Badarni, M.; Cohen, L.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Navigating a newly diagnosed cancer through clinician-facilitated discussions of health-related patient values: A qualitative analysis
    Journal Article

    Lynch, K. A.; Bernal, C.; Romano, D. R.; Shin, P.; Nelson, J. E.; Okpako, M.; Anderson, K.; Cruz, E.; Desai, A. V.; Klimek, V. M.; more...
    BMC Palliative Care (2022)

    Fulltext@MSK | Save
  • Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for metachromatic leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi)
    Journal Article

    Schoenmakers, D. H.; Beerepoot, S.; van den Berg, S.; Adang, L.; Bley, A.; Boelens, J. J.; Fumagalli, F.; Goettsch, W. G.; Grønborg, S.; Groeschel, S.; more...
    Orphanet Journal of Rare Diseases (2022)

    Fulltext@MSK | Save
  • Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
    Journal Article

    Lutz, M. S.; Klimovich, B.; Maurer, S.; Heitmann, J. S.; Märklin, M.; Zekri, L.; Jung, G.; Salih, H. R.; Hinterleitner, C.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: A preclinical model and initial clinical experience
    Journal Article

    Palomba, M. L.; Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Rivière, I.; Sadelain, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies
    Journal Article

    Park, J. A.; Cheung, N. V.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
    Journal Article

    Ghosh, N.; Postow, M.; Zhu, C.; Jannat-Khah, D.; Li, Q. Z.; Vitone, G.; Chan, K. K.; Bass, A. R.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save